These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17259483)

  • 1. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
    Marrero DG; Crean J; Zhang B; Kellmeyer T; Gloster M; Herrmann K; Rubin R; Fineberg N; Kolterman O
    Diabetes Care; 2007 Feb; 30(2):210-6. PubMed ID: 17259483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
    Hollander P; Maggs DG; Ruggles JA; Fineman M; Shen L; Kolterman OG; Weyer C
    Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.
    Rubin RR; Peyrot M
    Curr Med Res Opin; 2007 Aug; 23(8):1919-29. PubMed ID: 17624233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.
    Rubin RR; Peyrot M
    Diabetes Educ; 2009; 35(1):136-46. PubMed ID: 19244569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
    Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
    Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
    Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
    Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
    Herrmann K; Brunell SC; Li Y; Zhou M; Maggs DG
    Adv Ther; 2016 May; 33(5):848-61. PubMed ID: 27071768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
    Ratner R; Whitehouse F; Fineman MS; Strobel S; Shen L; Maggs DG; Kolterman OG; Weyer C
    Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):199-204. PubMed ID: 15891954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
    Maggs D; Shen L; Strobel S; Brown D; Kolterman O; Weyer C
    Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
    Thompson RG; Pearson L; Schoenfeld SL; Kolterman OG
    Diabetes Care; 1998 Jun; 21(6):987-93. PubMed ID: 9614619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
    Hollander P; Ratner R; Fineman M; Strobel S; Shen L; Maggs D; Kolterman O; Weyer C
    Diabetes Obes Metab; 2003 Nov; 5(6):408-14. PubMed ID: 14617226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.
    Herman WH; Ilag LL; Johnson SL; Martin CL; Sinding J; Al Harthi A; Plunkett CD; LaPorte FB; Burke R; Brown MB; Halter JB; Raskin P
    Diabetes Care; 2005 Jul; 28(7):1568-73. PubMed ID: 15983302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.